Palladio Biosciences
is a biopharmaceutical company that develops drug therapeutics for the treatment of polycystic kidney disease... Read morePalladio Biosciences
is a biopharmaceutical company that develops drug therapeutics for the treatment of polycystic kidney disease... Read more
2015
2836 NAICS listing
News
Nov 17, 2020
FinanzNachrichten
Palladio Biosciences: Palladio Biosciences, Inc.: Palladio Biosciences Announces First Patient Dosed With Lixivaptan in The ALERT Study, a Phase 3 Study of ADPKD Patients Previously Discontinued From Treatment With Tolvaptan Due to Liver Toxicity
Oct 20, 2020
MarketScreener
Palladio Biosciences: Palladio Biosciences Announces Presentation of Data from a Study of Lixivaptan Use in an ADPKD Patient who Previously Experienced Liver Toxicity with Tolvaptan During the American Society of Nephrology Kidney Week 2020 Meeting
Sep 29, 2020
Global University Venturing
Palladio Biosciences: Palladio fills palette with $20m - Global University Venturing
Sep 25, 2020
MarketScreener
Palladio Biosciences: Palladio Completes $20 Million Series B Financing
Sep 25, 2020
FierceBiotech
Palladio Biosciences: Palladio bags $20M to take once-discarded drug through phase 3
Nov 05, 2019
BioPortfolio
Palladio Biosciences: Palladio Biosciences Announces Presentations of ELiSA Phase 2 Study Results and Phase 3 Lixivaptan Clinical Program Design during the American Society of Nephrology Kidney Week 2019 Meeting
Dec 18, 2018
PharmiWeb
Palladio Biosciences: Palladio Biosciences Announces Dosing of First Patients with Lixivaptan in ELiSA, a Phase 2 Clinical Study in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
May 08, 2018
BioPortfolio
Palladio Biosciences: Palladio Biosciences Receives FDA IND Clearance to Begin the ELISA Study a Phase 2 Clinical Trial with Lixivaptan in Patients with Autosomal Dominant Polycystic Kidney Disease ADPKD
Nov 01, 2017
BioPortfolio
Palladio Biosciences: Palladio Biosciences Announces Presentations of New Data for Lixivaptan and Polycystic Kidney Disease during the American Society of Nephrology 2017 Annual Meeting
Oct 04, 2017
BioSpace
Palladio Biosciences: <b>Palladio Biosciences</b> Receives Orphan Drug Designation From The FDA For Lixivaptan For The Treatment Of Autosomal Dominant Polycystic Kidney Disease
Palladio Biosciences Competitors
1
2
3
4
5
6
7
8
9
10